MVA-member Mercodia, a Swedish biotech company focused on providing bioanalytical services and biomarker assays to the pharmaceutical industry and academia, announced that the company is expanding its capabilities to provide bioanalytical testing for preclinical and clinical programs with the opening of a service facility in the USA.
The new US bioanalytical laboratory represents an expansion of Mercodia’s capabilities and is in line with the company’s business strategy to provide outsourced bioanalytical support for drug development with a focus on large molecules, peptides, and oligonucleotides on a global scale.
“We are pleased to expand our global presence in bioanalytical services with a local presence in the largest market. Mercodia is a trusted partner for companies seeking support in the development and commercialization of their products. The new facility in the US is another step for Mercodia to become a major player in the global life science industry,” said Jörgen Dahlström, CEO of Mercodia.